Trump Secures Drug Pricing Deal with Nine Pharma Firms Including Amazon
On August 31, 2026, President Trump announced a new drug pricing agreement with nine pharmaceutical companies. This deal aims to align U.S. drug prices with lower rates charged abroad.
The involved companies include Amazon.com Inc., Alcon, Astellas Pharma, and others. They will have to adjust their pricing strategies to comply with this agreement, which could lead to increased scrutiny of pricing practices across the healthcare sector.
Amazon's involvement in pharmaceuticals is through its international segments, which contribute about 22% of the company's total revenue. The company generates revenue from various segments, including retail (74%), Amazon Web Services (17%), and advertising services (9%).
The market appears to be optimistic about Amazon's ability to generate revenue in the future, but this optimism is not without risk. Amazon's current Price-to-Sales ratio is significantly higher than its historical median of approximately 3.4x.